Question 1

Who’s an appropriate candidate to discuss ketamine therapy or Spravato?

Accepted Answer

In clinical practice, it’s reasonable to introduce ketamine therapy or esketamine (Spravato) when a patient with major depressive disorder has had diminishing returns or non-response to standard monoaminergic strategies, or when symptom severity, suicidality, or functional collapse shortens the runway to wait another 6–8 weeks. Patients who explicitly ask about alternatives are also good candidates for a balanced discussion, even if you ultimately decide together to defer. Before referring, consider a brief screen for medical and psychiatric safety factors (cardiovascular history, medications that may interact, substance use risk, and history of psychosis)—not to gatekeep, but to shape the next step thoughtfully. For some, the conversation alone restores agency and hope; for others, it becomes a coordinated trial in a Spravato clinic with clear goals and stop criteria. The north star is fit: Does ketamine treatment make sense for this person, at this moment, with this support system? Framed this way, you’re not selling ketamine for depression—you’re opening a clinically appropriate option and letting the patient remain in control.

Question 2

How do I coordinate with a Spravato clinic without losing the thread of care?

Accepted Answer

Expect a consultative model that keeps you at the helm. A high-quality Spravato clinic will (1) notify you at first consideration, (2) share a proposed care plan with indications, dosing rationale, and measurement strategy, (3) provide interval updates during ketamine treatment (often including PHQ-9, GAD-7, and functional notes), and (4) send a concise summary at dose adjustments, pauses, or discontinuation. You set communication cadence up front—weekly, bi-weekly, or at key milestones—so information flow supports rather than overwhelms. Medication changes outside ketamine therapy remain your call unless you explicitly delegate. When the acute series ends, you and the clinic co-author next steps: maintenance, transition back to your sole care, or alternative pathways. In short, collaboration should feel like an academically-affiliated consult service—expert input, warm handoffs, and zero ambiguity about who is guiding longitudinal care.

Question 3

How do I talk through stigma or my own uncertainty?

Accepted Answer

Patients take their cue from your stance. It’s clinically honest to say, “I hold both curiosity and caution here.” You might add: “Ketamine treatment and Spravato aren’t cures, and they won’t help everyone. In some patients, they can create a short window where change feels more possible. If we explore it, you stay in charge and we proceed stepwise.” Naming common myths helps without defensiveness: medical ketamine for depression is delivered in controlled settings with monitoring; misuse risk is managed by structure, not minimized by rhetoric. If your skepticism outweighs trust, pause and revisit when you can genuinely hold doubt and hope together—patients sense performative enthusiasm. When you do proceed, align on shared goals (sleep, self-care, suicidality, function) and a clear off-ramp if ketamine therapy isn’t helping. That stance reduces stigma by replacing hype with steady, transparent care.

Question 4

What should I expect from a high-quality Spravato clinic partner?

Accepted Answer

Three pillars—accountability, expertise, and warmth—show up in tangible ways. Look for a psychiatry-led, academically-affiliated team with REMS processes, clear medical oversight, and comfort making decisions in gray zones (e.g., when to slow titration, how to navigate side effects, when to pause). Safety is visible: vitals monitoring, adverse-event pathways, and staff trained to support dissociation and anxiety in real time. Communication is proactive and bidirectional: a named contact person, agreed cadence, and rapid replies to your questions. Care is measurement-informed but human: outcomes tracked and shared, yet never weaponized against the patient. You should also see practical transparency—costs, scheduling, transportation guidance, and expectations between visits (e.g., psychotherapy or behavioral support). If the culture is welcoming and the clinical notes make your job easier, you’ve likely found a Spravato clinic that will elevate—not fragment—your patient’s care.

Question 5

What should my patient expect during sessions?

Accepted Answer

Set a calm, specific frame. Patients typically arrive having followed simple prep (brief fasting if advised, comfortable clothing, a plan for a safe ride home). In the clinic, they’ll check vitals, review consent, and receive dosing (with Spravato treatment, intranasal esketamine is self-administered under supervision). Common effects—dissociation, dizziness, nausea, shifts in time perception—are usually short-lived and monitored; staff remain present throughout. Observation continues for a defined period (often around two hours for Spravato) with repeat vitals and supportive measures as needed. After discharge, no driving or risky tasks that day; instead, gentle routines, hydration, and low-stakes activities are encouraged. Many patients find it helpful to schedule psychotherapy or behavioral support within the neuroplasticity window to practice small, doable changes. The tone is: safe, supported, predictable—and still entirely the patient’s choice to continue, adjust, or stop.

Question 6

Where can I send patients for plain-English explanations?

Accepted Answer

Provide a short, trustworthy bundle and keep it consistent. Please feel encouraged to point patients to Lumin Health’s pages on How Ketamine Works (glutamate, NMDA/AMPA, and why speed can differ), Neuroplasticity Window (what the first 24–72 hours are good for), Spravato vs Off-Label (routes, schedules, monitoring), Therapy + Ketamine (how to pair sessions with psychotherapy or behavioral support), and Routes & Bioavailability (why delivery method matters). Many clinicians print a one-page handout with QR codes so patients can read at their own pace and return with questions. If you partner with Lumin Health, these patient-facing resources are designed to be stigma-aware, brief, and shareable—use them as common language across your team. The goal isn’t to persuade; it’s to orient. When patients understand the “why,” the “whether” of ketamine therapy or Spravato becomes a genuinely informed choice.